Torticollis, Dystonia Clinical Trial
Official title:
OnabotulinumtoxinA in the Management of Psychogenic Dystonia
The purpose of this research study is to evaluate if patients with psychogenic dystonia treated with onabotulinumtoxinA (BOTOX) injections will demonstrate lower severity and disability at one month and at three months than those having received placebo injections
Specific Aim 1: To investigate the effect of BoNT on PsyD severity and disability.
We will measure the changes in severity, duration, and incapacitation scores of the Rating
Scale for Psychogenic Movement Disorders (RSPMD)10 in adult patients with clinically definite
PsyD one month after intramuscular injections with onabotulinumtoxinA in selected muscles of
the affected limb(s).
H1: PsyD patients treated with onabotulinumtoxinA injections will demonstrate lower severity
and disability at one month than those having received placebo injections.
Specific Aim 2: To investigate the effect of CBT on PsyD severity and disability with and
without BoNT pretreatment.
We will examine the extent to which any changes in severity and disability of PsyD, as
measured by the RSPMD, after 12 weekly CBT sessions, can be influenced by pre-CBT injections
with onabotulinumtoxinA.
;